ExLibris header image
SFX Logo
Title: Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis
Source:

International Journal of Cancer [0020-7136] Buchhalter, Ivo yr:2018


Collapse list of basic services Basic
Full text
Full text available via Wiley Online Library All Journals
GO
Full text available via Wiley Online Library Full Collection 2019
GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Chae, Young K. "Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer." Clinical lung cancer (2018). Link to SFX for this item
2. Hellmann, Matthew D. "Lung Cancer with a High Tumor Mutational Burden." The New England Journal of Medicine 379.11 (2018): 1093-1094. Link to SFX for this item
3. Hellmann, Matthew D. "Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer." Cancer cell. 33.5: 791-793. Link to SFX for this item
4. "A Joint Approach to Immunotherapy Biomarkers." Cancer Discovery (2018). Link to SFX for this item
5. Ahmadzada, T. "An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer." Journal of Clinical Medicine (2018). Link to SFX for this item
6. Oxnard, Geoffrey R. "Does TMB impact the effectiveness of TKIs in EGFR-mutant NSCLC?" Clinical Cancer Research 25.3 (2018): 899-900. Link to SFX for this item
7. Rizvi, H. "Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing." Journal of clinical oncology 36.7 (2018): 633-641. Link to SFX for this item
8. Majem, M. "Small-cell lung cancer in the era of immunotherapy." Translational Lung Cancer Research 6.Suppl 1 (2017). Link to Full Text for this item Link to SFX for this item
9. Janakiram, M. "HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status." Clinical cancer research 23.3 (2016): 825-832. Link to SFX for this item
10. Hellmann, Timothy N. "Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer." Science 348.6230 (2015): 124-8. Link to SFX for this item
11. Brown, Scott D. "Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival." Genome research 24.5 (2014): 743-750. Link to Full Text for this item Link to SFX for this item
12. Vietz, Roman A. "Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing." Nature biotechnology 31.11 (2013): 1023-31. Link to SFX for this item
13. Bouffet, E. "Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency." Journal of clinical oncology 34.19 (2016): 2206-2211. Link to SFX for this item
14. Hugo, W. "Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma." Cell 165.1 (2016): 35-44. Link to SFX for this item
15. Koyama, S. "STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T cell activity in the lung tumor microenvironment." Cancer research 76.5 (2016): 999-1008. Link to SFX for this item
16. West, A. "PD-1 blockade induces responses by inhibiting adaptive immune resistance." Nature 515.7528 (2014): 568-571. Link to Full Text for this item Link to SFX for this item
17. Chang, K. "Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis." Critical care 18.1 (2014). Link to Full Text for this item Link to SFX for this item
View More...
View Less...
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.